Vascular endothelial growth factor, soluble Fms-like tyrosine kinase 1, and the severity of coronary artery disease

Angiology

Volumn 62, Issue 2, 2011, Pages 176-183

  Kim, Soo Young ^a   Lee, Sang Hak ^a   Park, Sungha ^a   Kang, Seok Min ^a   Chung, Namsik ^a   Shim, Won Heum ^a   Cho, Seung Yun ^a   Sun Ha Jee, ^b   Manabe, Ichiro ^c   Jang, Yangsoo ^a  

^a Yonsei University Health System   (South Korea)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

atherosclerosis; coronary artery disease; vascular endothelial growth factor receptor 1; vascular endothelial growth factors

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD135 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTENSIVE AGENT; VASCULOTROPIN;

ADULT; AGE; AGED; ARTICLE; BLOOD VESSEL; CAROTID ARTERIOGRAPHY; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HEART INFARCTION; HISTORY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SMOKING; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 78651410622     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319710370963     Document Type: Article

References (30)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004 ; 25 (4). 581-611.
2. Gerber HP, Condorelli F., Park J., Ferrara N. Differential transcriptional regulation of the two VEGF receptor genes, Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem. 1997 ; 272 (38). 23659-23667.
3. Kendall RL, Thomas KA Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A. 1993 ; 90 (22). 10705-10709.
4. Inoue M., Itoh H., Ueda M., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998 ; 98 (20). 2108-2116.
5. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol. 2001 ; 87 (6). 805-807.
6. Blann AD, Belgore FM, Constans J., Conri C., Lip GY Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol. 2001 ; 87 (10). 1160-1163.
7. Blann AD, Belgore FM, McCollum CN, Silverman S., Lip PL, Lip GY Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary artery or peripheral atherosclerosis, or type II diabetes. Clin Sci. 2002 ; 102 (2). 187-194.
8. Maynard SE, Min JY, Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 ; 111 (5). 649-658.
9. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M., Murphy SR, Granger JP Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008 ; 294 (2). H541 - H550.
10. Chung NA, Lydakis C., Belgore F., Li-Saw-Hee FL, Blann AD, Lip GY Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart. 2003 ; 89 (12). 1411-1415.
11. Alber HF, Frick M., Dulak J., et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart. 2005 ; 91 (3). 365-366.
12. Fleish M., Billinger M., Eberli FR, Garachemani AR, Meier B., Seiler C. Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation. 1999 ; 100 (19). 1945-1950.
13. Nakajima K., Tabata S., Yamashita T., et al. Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease. Clin Cardiol. 2004 ; 27 (5). 281-286.
14. Hojo Y., Ikeda U., Zhu Y., et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol. 2000 ; 35 (4). 968-973.
15. Chung NA, Lydakis C., Belgore F., Blann AD, Lip GY Angiogenesis in myocardial infarction. An acute or chronic process ? Eur Heart J. 2002 ; 23 (20). 1604-1608.
16. Sandhofer A., Tatarczyk T., Kirchmair R., et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis. 2009 ; 206 (1). 265-269.
17. Sugimoto H., Hamano Y., Charyntan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor (sFlt-1) induces proteinuria. J Biol Chem. 2003 ; 278 (15). 12605-12608.
18. Zhao Q., Egashira K., Hiasa K., et al. Essential role of vascular endothelial growth factor and flt-1 signals in neointima formation after periadventitial injury. Arterioscler Thromb Vasc Biol. 2004 ; 24 (12). 2284-2289.
19. Koga J., Matoba T., Egashira K., et al. Soluble Flt-1 gene transfer ameliorates neointima formation after wire injury in flt-1 tyrosine kinase-deficient mice. Arterioscler Thromb Vasc Biol. 2009 ; 29 (4). 458-464.
20. Onoue K., Uemura S., Takeda Y., et al. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation. 2009 ; 120 (24). 2470-2477.
21. Felmeden DC, Blann AD, Lip GY Angiogenesis: basic pathophysiology and implication for disease. Eur Heart J. 2003 ; 24 (7). 586-603.
22. Li J., Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, Flk-1, and Flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 1996 ; 270 (5 pt 2). H1803 - H1811.
23. Hazarika S., Dokun AO, Li Y., Popel AS, Kontos CD, Annex BH Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: different regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007 ; 101 (9). 948-956.
24. Scheufler KM, Drevs J., van Velthoven V., et al. Implication of vascular endothelial growth factor, sFlt-1, and sTie-2 in plasma, serum and cerebrospinal fluid during cerebral ischemia in man. J Cereb Blood Flow Metab. 2003 ; 23 (1). 99-110.
25. Kodama Y., Kitta Y., Nakamura T., et al. Atorvastatin increases plasma soluble fms-like tyrosine kinase-1 and decrease vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol. 2006 ; 48 (1). 43-50.
26. Lieb W., Safa R., Benjamin EJ, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J. 2009 ; 30 (9). 1121-1127.
27. Sasso FC, Torella D., Carbonara O., et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol. 2005 ; 46 (5). 827-834.
28. Garvin S., Nilsson UW, Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br J Cancer. 2005 ; 93 (9). 1005-1010.
29. Schmidt-Lucke C., Belgore F., Reinhold D., et al. Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial function in healthy smokers. Int J Cardiol. 2005 ; 100 (2). 207-212.
30. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the ''chicken-and-egg'' question. Endocrinology. 2004 ; 145 (11). 4835-4837.